Camp4 Therapeutics Corp
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
ONE KENDALL SQUARE, CAMBRIDGE, MA, 02139
Mailing Address
ONE KENDALL SQUARE, CAMBRIDGE, MA, 02139
Phone
617-651-8867
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$117.81M
Total Assets
$109.52M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 3 Initial insider ownership report | April 3, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
Annual Reports
10-K
March 5, 2026
- Lead therapeutic candidate CAMP-001 successfully moved into Phase 1 clinical trials with initial positive safety and tolerability data.
- Proprietary RNA-targeting platform further developed, boosting ability to identify and create new drug candidates.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.